Non-Hodgkin's lymphoma of Waldeyer's ring and nasal cavity. Clinical and immunologic aspects

Abstract

Twenty-nine cases of non-Hodgkin's lymphoma of Waldeyer's ring (W-NHL) and nasal cavity or paranasal sinus (N-NHL) were studied for tumor-surface marker phenotype and histopathologic correlation with clinical features. Immunostaining procedures on tissue sections by using xenoantisera and monoclonal antibodies to human B- and T-cells enabled the authors to demonstrate precise surface marker phenotypes of tumor cells and, moreover, the histologic localization of normal or neoplastic B- and T-cells in preserving the original structure of lymphoid organs or tumor tissues. In 22 cases of W-NHL, 19 (86%) had B-cell markers and 3 (14%) had T-cell markers, whereas 6 of 7 cases (86%) of N-NHL had T-cell markers. Tumor cells in T-cell lymphomas in W-NHL and N-NHL reacted with antibodies to peripheral T-cells except one case of W-NHL. Rappaport "histiocytic" subtype was heterogeneous with respect to both surface marker characteristics and morphologic features, i.e., seven had B-cell markers and four had T-cell markers, and they were all subdivided into "large cell" or "large cell, immunoblastic" in Working Formulation and "large cell" or "pleomorphic" in Lymphoma Study Group classification. The actuarial survival curve for all T-cell lymphoma patients was characterized by a rapid initial decline and a subsequent plateau, which contained two of the long survivors. In contrast, the B-cell lymphoma group had a more graded decline. The median and actuarial survivals of the T-cell lymphoma group were far inferior to those for the lymphoma group that expressed B-cell markers.

Primary diffuse large B‐cell lymphoma of the tonsil

“…Other studies have also found size and stage of disease to be poor prognostic factors. 6,7,21 In our current series, WHO performance score 2, the presence of B-symptoms, tumor bulk [7 cm, and higher Ann Arbor stage were associated with inferior outcome (Table 2). On multivariate analysis, a performance score 2 and the presence of 'B' symptoms retained their poor prognostic significance (Table 3).…”

“…Furthermore, a majority of these patients (60%-70%) present with early stage (stages I and II) disease. 6,7 Gao et al 19 reported 69.6% of their patients to have localized (stage I or II) disease, whereas in the series by Mohammadianpanah et al 17 18% of patients had stage I and 67% had stage II disease. From January 1990 to December 2002, 148 patients with NHL involving the tonsil were treated at the Tata Memorial Hospital, Mumbai.…”

“…[6][7][8][9] Treatment approaches that have been used include radiotherapy (RT) alone, chemotherapy (CTh) alone, or a combination of both (CTh 1 RT). 5,10 Most series in the literature have reported results of treating lymphomas of the Waldeyer ring as a group and the resultant diversity of primary site, histology, presentation, therapeutic modality, and outcome makes it difficult to draw meaningful conclusions from these studies.…”

Role of Epstein-Barr virus and interleukin 6 in the development of lymphomas of human origin in SCID mice engrafted with human tonsillar mononuclear cells

“…Recently, the demonstration of the EBV/C3d receptor on cells from the stratified squamous epithelium of the oropharynx (Young et al, 1986;Talacko et al, 1991), which also covers the tonsils, has lead to the current hypothesis that this epithelium plays an important role in EBV persistence and the pathogenesis of B cell tumours (Allday & Crawford, 1988). In view of these findings, the observation of human palatine tonsils as a potential source of the EBVassociated lymphomas reported here is of particular importance.…”

Primary mantle cell lymphoma of tonsil: Case report

“…Тонзиларни лимфоми имају добру прогнозу 5 . Већина ових пацијената има локализовану болест 6,7,8,9 , стадијум 1 или 2. Код пацијената са раним стадијумом болести без обимних маса, петогодишње преживљавање је 65%-85% 3,8,10,11 .…”